摘要
近年来，68Ga标记的多肽PET/CT显像为神经内分泌肿瘤（NET）的诊断提供了新的方法和视角。68Ge/68Ga发生器已经商业化，容易获得，并且68Ga标记过程简单方便，显像剂稳定性好。在此基础上，越来越多的研究比较了68Ga标记的多肽PET/CT与传统的形态学显像方法（CT、MRI）及生长抑素受体扫描对NET病灶的诊断效能，发现68Ga标记的多肽PET/CT远远优于后者。此外，68Ga标记的多肽PET/CT显像还能为患者治疗方案的选择、辐射剂量的调整甚至预后效果的评估提供多种重要信息，其有望成为NET患者肿瘤显像的临床首选。笔者就近年来68Ga标记的多肽PET/CT显像在临床上的初步应用研究作一综述。
In recent years, 68Ga-labelled peptides PET/CT has provided a new approach and pe-rspective for the diagnosis of neuroendocrine tumors （NET）. 68Ge/68Ga generator has been commercial-ized, with 68Ga obtained easily. The labeling process is easy, and the 68Ga-labelled peptides are stable. There are an increasing number of reports about the much better diagnostic performance of 68Ga-labelled peptides PET/CT for the detection of NET lesions as compared to traditional morphological imaging proce-dures （CT, MRI） and somatostatin receptor scintigraphy. In addition, it can offer important clinical infor-mation in selecting treatment plan, adjusting the radiation dose and assessing the prognosis. 68Ga-labelled peptides PET/CT is expected to be the standard method and first choice for imaging NET. An overview about the introduction and application of 68Ga-labelled peptides PET/CT in clinical practice is presented.
出处
《国际放射医学核医学杂志》
2015年第1期75-79,共5页
International Journal of Radiation Medicine and Nuclear Medicine
基金
国家自然科学基金（81171456
81271532/H1801）
